0001209191-20-021178.txt : 20200325
0001209191-20-021178.hdr.sgml : 20200325
20200325184702
ACCESSION NUMBER: 0001209191-20-021178
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200323
FILED AS OF DATE: 20200325
DATE AS OF CHANGE: 20200325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cui Jingrong Jean
CENTRAL INDEX KEY: 0001772259
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38871
FILM NUMBER: 20743502
MAIL ADDRESS:
STREET 1: C/O TURNING POINT THERAPEUTICS, INC.
STREET 2: 10628 SCIENCE CENTER DR., STE. 225
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc.
CENTRAL INDEX KEY: 0001595893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463826166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-926-5251
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: TP Therapeutics, Inc.
DATE OF NAME CHANGE: 20181018
FORMER COMPANY:
FORMER CONFORMED NAME: TP Therapeutics, INC
DATE OF NAME CHANGE: 20140106
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-23
0
0001595893
Turning Point Therapeutics, Inc.
TPTX
0001772259
Cui Jingrong Jean
C/O TURNING POINT THERAPEUTICS, INC.
10628 SCIENCE CENTER DRIVE, STE. 200
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
1001298
D
Common Stock
300000
I
By The Jean Cui 2020 GRAT
Common Stock
2020-03-23
4
S
0
900
36.52
D
824483
I
By spouse
Common Stock
2020-03-23
4
S
0
1900
37.88
D
822583
I
By spouse
Common Stock
2020-03-23
4
S
0
3000
38.77
D
819583
I
By spouse
Common Stock
2020-03-23
4
S
0
1200
39.63
D
818383
I
By spouse
Common Stock
2020-03-24
4
S
0
1300
40.75
D
817083
I
By spouse
Common Stock
2020-03-24
4
S
0
3200
41.73
D
813883
I
By spouse
Common Stock
2020-03-24
4
S
0
2100
42.72
D
811783
I
By spouse
Common Stock
2020-03-24
4
S
0
400
43.58
D
811383
I
By spouse
Common Stock
2020-03-25
4
S
0
2100
44.56
D
809283
I
By spouse
Common Stock
2020-03-25
4
S
0
13292
45.35
D
795991
I
By spouse
Common Stock
2020-03-25
4
S
0
2200
46.50
D
793791
I
By spouse
Common Stock
2020-03-25
4
S
0
200
47.11
D
793591
I
By spouse
Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
The weighted average sale price for the transaction reported was $36.52, and the range of prices were between $36.225 and $36.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $37.88, and the range of prices were between $37.35 and $38.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $38.77, and the range of prices were between $38.37 and $39.235. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $39.63, and the range of prices were between $39.38 and $39.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $40.75, and the range of prices were between $40.30 and $41.280. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $41.73, and the range of prices were between $41.30 and $42.240. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $42.72, and the range of prices were between $42.30 and $43.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $43.58, and the range of prices were between $43.345 and $43.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $44.56, and the range of prices were between $43.97 and $44.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $45.35, and the range of prices were between $44.97 and $45.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $46.50, and the range of prices were between $46.09 and $47.005. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $47.11, and the range of prices were between $47.105 and $47.11. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Annette North, Attorney-in-Fact
2020-03-25